Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent Trial

Institute and Comprehensive Center for Inflammation Medicine, University of L übeck, Lübeck Germany; Jeffrey J. Crowley, Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA; Caitriona Ryan, Charles’ Institute of Dermatology, University College Dublin, Ireland; James G. Krueger, Laboratory for Investigative Dermatology, The Rockefeller University, New Yo rk, NY; Tsen-Fang Tsai, Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Mary Flack, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT; Yihua Gu, AbbVie Inc, North Chicago, IL; Tianshuang Wu, AbbVie Inc, North Chic ago, IL; David A.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research